Finally, in terms of TKI therapies, PD-L1 gene expression, using Real-Time PCR, in CTC fractions isolated by Parsortix from NSCLC patients treated with Osimertinib (a subset of the patients was used in this study for single cell analysis) has been shown to be low (10%; 3 out of 30 patients) at baseline, to increase after the first cycle of treatment (28%; 7 out of 25) and further increase at EOT (35%; 9 out of 26) [19]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.